FindTrial
Sign In

A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503869-34-00
Acronym
CC-91633-AML-001
Enrollment
48
Registered
2023-03-13
Start date
2022-03-15
Completion date
2025-06-04
Last updated
2025-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia or myelodysplastic syndrome of high risk group, that has come back after treatment or cannot be cured or treated by any other known therapies.

Interventions

None listed

Sponsors

Celgene Corp.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026